Skip to main content

Table 1 Pretreatment clinical characteristics

From: Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Clinical characteristics Value
Patients (n) 30
Age (yr.)  
  Median (mean) 68 (65.9)
  Range 52-76
ECOG 30 (100%)
  0  
Prostate specific antigen (ng/ml)  
  Median (mean) 25.8 (43.2)
  Range 2.1-293.0
Gleason score at diagnosis  
  6 3 (10.0%)
  7 14 (46.7%)
  8 6 (20.0%)
  9 7 (23.3%)
Clinical stage  
  T2c 2 (6.7%)
  T3a 6 (20.0%)
  T3b 21 (70.0%)
  T4 1 (4.3%)
Kattan score  
  Median (mean) 172 (171)
  Range 125-200
Probability of 5-year bRFS (%)  
  Median (mean) 10 (10)
  Range 0-55
  1. Abbreviation: bRFS, biochemical recurrence free survival.